Galanin acts at GalR1 receptors in spinal antinociception: synergy with morphine and AP-5.
The neuropeptide galanin (Gal) and its receptors (GalR1, GalR2, and GalR3) are expressed in spinal cord. We have characterized the pharmacology of the antinociceptive effects of intrathecally (i.t.) administered galanin and its analogs in the formalin test in rats, using an automated flinch detection system. Intrathecal injection of rat galanin (Gal(1-29)) or human galanin (Gal(1-30)) produced a dose-dependent inhibition of formalin-evoked flinching in phase 2, but not in phase 1. Relative potency of galanin homologs is Gal(1-29) >or= Gal(1-30) > galanin-like peptide(1-24) >or= Gal(2-11) = Gal (3-29) (an inactive analog). Galanin(1-29) and Gal(1-30) are both high-affinity agonists to GalR1/R2, whereas Gal(2-11) is a GalR2 receptor agonist. Our data suggest that i.t. galanin-produced antinociception is mediated by activation of GalR1 receptors. When comparing antinociceptive effects of i.t. Gal(1-29) to morphine and to 2-amino-5-phosphonopentanoic acid (AP-5, an N-methyl-d-aspartate antagonist), Gal(1-29) is of intermediate potency between these two analgesic agents based on the ED(50) values. An isobolographic analysis showed synergy between Gal(1-29) and morphine and between Gal(1-29) and AP-5 on the second phase. Fixed ratio dose combinations of morphine and Gal(1-29), or AP-5 and Gal(1-29) produced significantly greater antinociception than predicted from simple additivity. In summary, the present findings reveal that 1) spinal galanin produces a reliable inhibition of formalin-induced facilitated nociceptive processing, an effect possibly mediated by GalR1 receptors; and 2) galanin potentiates i.t. morphine and AP-5-induced antinociception.
Hua
Xiao-Ying
XY
Department of Anesthesiology, University of California, San Diego, La Jolla, CA 92103-0818, USA. xyhua@ucsd.edu
Hayes
Carol S
CS
Hofer
Anthony
A
Fitzsimmons
Bethany
B
Kilk
Kalle
K
Langel
Ulo
U
Bartfai
Tamas
T
Yaksh
Tony L
TL
D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology* / Q000627:therapeutic use; D000700:Analgesics / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D004195:Disease Models, Animal; D004357:Drug Synergism; D019004:Galanin / Q000031:analogs & derivatives / Q000494:pharmacology* / Q000627:therapeutic use; D007278:Injections, Spinal; D008297:Male; D009020:Morphine / Q000494:pharmacology* / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy*; D051381:Rats; D017207:Rats, Sprague-Dawley; D044091:Receptor, Galanin, Type 1 / Q000187:drug effects / Q000378:metabolism*; D013116:Spinal Cord / Q000187:drug effects*
D000700:Analgesics; D044091:Receptor, Galanin, Type 1; D015763:2-Amino-5-phosphonovalerate; D009020:Morphine; D019004:Galanin